PMID- 31576546
OWN - NLM
STAT- MEDLINE
DCOM- 20191004
LR  - 20230513
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1164
DP  - 2019
TI  - Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in 
      Prostate Cancer Patients.
PG  - 141-150
LID - 10.1007/978-3-030-22254-3_11 [doi]
AB  - Patients presenting with prostate cancers undergo clinical staging evaluations to 
      determine the extent of disease to guide therapeutic recommendations. Management 
      options may include watchful waiting, surgery, or radiation therapy. Thus, 
      initial risk stratification of prostate cancer patients is important for 
      achieving optimal therapeutic results or cancer cure and preservation of quality 
      of life. Predictive biomarkers for risks of complications or late effects of 
      treatment are needed to inform clinical decisions for treatment selection. Here, 
      we analyzed pre-treatment plasma metabolites in a cohort of prostate cancer 
      patients (N = 99) treated with Stereotactic Body Radiation Therapy (SBRT) at 
      Medstar-Georgetown University Hospital in a longitudinal, quality-of-life study 
      to determine if individuals experiencing radiation toxicities can be identified 
      by a molecular profile in plasma prior to treatment. We used a multiple reaction 
      mass spectrometry-based molecular phenotyping of clinically annotated plasma 
      samples in a retrospective outcome analysis to identify candidate biomarker 
      panels correlating with adverse clinical outcomes following radiation therapy. We 
      describe the discovery of candidate biomarkers, based on small molecule 
      metabolite panels, showing high correlations (AUCs >/= 95%) with radiation 
      toxicities, suitable for validation studies in an expanded cohort of patients.
FAU - Cheema, Amrita K
AU  - Cheema AK
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
AD  - Department of Biochemistry, Molecular and Cellular Biology, Georgetown University 
      Medical Center, Washington, DC, USA.
FAU - Grindrod, Scott
AU  - Grindrod S
AD  - Shuttle Pharmaceuticals Inc, Rockville, MD, USA.
FAU - Zhong, Xiaogang
AU  - Zhong X
AD  - Department of Biostatistics and Biomathematics, Georgetown University Medical 
      Center, Washington, DC, USA.
FAU - Jain, Shreyans
AU  - Jain S
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Menon, Smrithi S
AU  - Menon SS
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Mehta, Khyati Y
AU  - Mehta KY
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Suy, Simeng
AU  - Suy S
AD  - Department of Radiation Medicine, Medstar-Georgetown University Hospital, 
      Washington, DC, USA.
FAU - Collins, Sean
AU  - Collins S
AD  - Department of Radiation Medicine, Medstar-Georgetown University Hospital, 
      Washington, DC, USA.
FAU - Wang, Yiwen
AU  - Wang Y
AD  - Department of Biostatistics and Biomathematics, Georgetown University Medical 
      Center, Washington, DC, USA.
FAU - Timofeeva, Olga
AU  - Timofeeva O
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University Medical Center, Washington, DC, USA.
FAU - Bandi, Gaurav
AU  - Bandi G
AD  - Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, 
      USA.
FAU - Pahira, John
AU  - Pahira J
AD  - Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, 
      USA.
FAU - Kowalczyk, Keith
AU  - Kowalczyk K
AD  - Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, 
      USA.
FAU - Lynch, John
AU  - Lynch J
AD  - Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, 
      USA.
FAU - Dritschilo, Anatoly
AU  - Dritschilo A
AD  - Shuttle Pharmaceuticals Inc, Rockville, MD, USA. dritscha@georgetown.edu.
AD  - Department of Radiation Medicine, Medstar-Georgetown University Hospital, 
      Washington, DC, USA. dritscha@georgetown.edu.
LA  - eng
GR  - P30 CA051008/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Biomarkers)
SB  - IM
MH  - *Biomarkers/blood
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - *Prostatic Neoplasms/radiotherapy
MH  - Quality of Life
MH  - *Radiation Injuries/blood
MH  - *Radiosurgery/adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Metabolomics
OT  - Prognostic biomarkers
OT  - Prostate cancer
OT  - SBRT
EDAT- 2019/10/03 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/10/03 06:00
PHST- 2019/10/03 06:00 [entrez]
PHST- 2019/10/03 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
AID - 10.1007/978-3-030-22254-3_11 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2019;1164:141-150. doi: 10.1007/978-3-030-22254-3_11.